Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.

Name: Kaimen Rigor review — Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.
Item: Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.
Rating: 39
Author: Alpha1

Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, Olsson DS, Perl S, Shibata H, Wang JG, Wilderäng U, Wittes J, Williams B, BaxHTN Investigators

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 1★ (Critical), 2 critical, 2 high issues for “Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.

Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, Olsson DS, Perl S, Shibata H, Wang JG, Wilderäng U, Wittes J, Williams B, BaxHTN Investigators

Read full text (PMC)

DOI

10.1056/NEJMoa2507109

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/3bf8085c-3ece-4c98-aae6-46fde7c90682" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/3bf8085c-3ece-4c98-aae6-46fde7c90682/badge" alt="Kaimen Rigor review — 1★ (Critical), 2 critical, 2 high issues for “Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

4993e021590f1746a22c242394ffd4b96bfaa11e616605fe65568374ffb595eb

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.

Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, Olsson DS, Perl S, Shibata H, Wang JG, Wilderäng U, Wittes J, Williams B, BaxHTN Investigators

Paper source

Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

1 / 5

Critical — a demonstrable failure

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

StatisticsImpossible or misreported statistic ×2−2★
IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
StatisticsPrinted percentage does not match its own count (capped) ×3−0.25★
ReportingData & code availability partially met−0.25★

A demonstrable critical failure caps the rating at the minimum, regardless of the deductions above.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 21 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Biggest issues2 demonstrable

01Printed percentage does not match its own countdemonstrable
criticalArithmeticrecomputedFull detail
19.1% does not match the reported count 49/264
“49 (19.1%)”
Safety
02Printed percentage does not match its own countdemonstrable
criticalArithmeticrecomputedFull detail
22.8% does not match the reported count 59/266
“59 (22.8%)”
Safety
03Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is change in seated systolic blood pressure (SBP), a surrogate for cardiovascular outcomes. The paper does not demonstrate target engagement at the tested doses (e.g., PK/PD or dose-exposure relationship) nor cite validated evidence linking SBP reduction to clinical outcomes in this context. Although SBP is a well-established surrogate for cardiovascular risk, the manuscript does not explicitly provide such validation or target engagement data.
“The primary efficacy end point was the change in seated-SBP, from baseline to week 12, assessed for each baxdrostat group versus placebo.”
Find in source
04Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
7% does not match the reported count 18/264
“18 (7.0%)”
Safety
05Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
12.6% does not match the reported count 33/264
“12.6%”
Safety
06Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
15.6% does not match the reported count 41/266
“15.6%”
Safety

Findings by category

301ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit6 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted phase 3 randomized controlled trial with rigorous design, clear reporting of ethics, demographics, and statistical methods. The main weakness is the absence of a data availability statement, which is a notable reporting gap for a clinical trial. Minor copyedit issues and a small discrepancy in the number randomized (794 vs 796) are also present.

Both reviewers independently scored all eight dimensions and agreed on every status. The study type is interventional (phase 3 RCT). The statistics verification component recomputed a subset of tests (12 total, 7 consistent, 5 inconsistent with no decision errors), but this does not affect the pass status; the unverified tests remain unconfirmed. The integrity check flagged a minor discrepancy in the number randomized (794 vs 796) and a low-severity internal contradiction that is not a true contradiction.

Numerical inconsistencies

3 findings · worst critical

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Recomputed 7 tests: 7 consistent, 0 inconsistent; 7 via agent-written checks. 2 reported summary statistics mathematically impossible for the stated N (PERCENT). 3 printed percentages that do not match their own count.

Overstated conclusions

2 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions only partially backed by the presented evidenceAssessed

5 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites prior work on aldosterone dysregulation, MRAs, and the phase 2 BrigHTN and HALO trials, acknowledging both positive and negative results. The rationale for testing baxdrostat is clearly derived from the need for an alternative to MRAs and the mixed results of prior trials. The paper does not explicitly describe how limitations of prior research are addressed, but the design of a larger phase 3 trial with a broader population implicitly addresses some limitations.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on aldosterone's role in hypertension and the limitations of current treatments, and it logically links this to the study's objectives.

Evidence

“In the 12-week phase 2 BrigHTN trial in patients with resistant hypertension, baxdrostat reduced seated office systolic blood pressure (seated-SBP) compared with placebo. However, in a phase 2 trial (HALO) in patients with uncontrolled hypertension, baxdrostat failed to show a difference in change from baseline in seated-SBP at week 8 versus placebo.”

Introduction ¶1Find in source

“An alternative therapeutic approach is direct inhibition of aldosterone synthase, which catalyzes the final three steps in aldosterone biosynthesis.”

Introduction ¶1Find in source

absence[Introduction]

The paper does not explicitly describe how limitations of prior research are addressed.

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior research on aldosterone's role in hypertension and the limitations of current treatments, and it logically motivates the study of baxdrostat.

Evidence

Introduction ¶1Find in source

“Here, we report the results of a longer-term, phase 3 trial assessing the efficacy and safety of baxdrostat in a broader population of patients with uncontrolled or resistant hypertension.”

IntroductionFind in source

The trial is described as randomized, double-blind, and placebo-controlled. Randomization was stratified by hypertension status and baseline SBP, but the specific method (e.g., random number generator) is not stated. Blinding is described as double-blind, and the open-label phases are clearly delineated. A power analysis is provided (720 participants for 98% power). Inclusion/exclusion criteria are summarized and referenced in the supplement. Outlier handling is addressed through pre-specified analysis populations and multiple imputation for missing data. The control group is placebo, and independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodINADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with clear randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria, though some details like the randomization method are not fully described.

Evidence

“Randomization was stratified by baseline hypertension status (uncontrolled hypertension, resistant hypertension) and baseline seated-SBP (<145, ≥145 mmHg).”

MethodsFind in source

“This multinational, randomized, double-blind, placebo-controlled phase 3 trial”

AbstractFind in source

“It was estimated that 720 participants would need to be randomized to achieve 98% power to detect a mean (standard deviation [SD]) difference of 6 (15) mmHg for change from baseline in seated-SBP at week 12 in favor of baxdrostat versus placebo using a two-sample t-test with a two-sided significance level of 0.025.”

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria, though some details on blinding and replication are not fully described.

Evidence

“Participants were randomly assigned 1:1:1 to receive baxdrostat 1 mg, baxdrostat 2 mg, or placebo once daily. Randomization was stratified by baseline hypertension status (uncontrolled hypertension, resistant hypertension) and baseline seated-SBP (<145, ≥145 mmHg).”

MethodsFind in source

Statistical analysisFind in source

Sex is reported for all participants, and both sexes are enrolled, so sex_justified is not applicable. Age, weight (via BMI), and health status (diabetes, eGFR) are reported. Demographics include age, sex, race/ethnicity, and comorbidities. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study reports key demographic and clinical characteristics including age, sex, race, and baseline blood pressure, which are adequate for a human trial.

Evidence

“Male sex – no. (%) | 162 (61.4) | 169 (64.0) | 163 (61.3)”

Table 1Find in source

paraphrase[Table 1]

“Race or ethnic group – no. (%) | White | 167 (63.3) | 165 (62.5) | 168 (63.2)”

“Diabetes – no. (%) | 110 (41.7) | 83 (31.4) | 110 (41.4)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, race, and baseline blood pressure, but some details on health status and comorbidities are limited.

Evidence

“Age – yrs | 61.9±11.6 | 59.8±11.8 | 61.8±11.7 | | Male sex – no. (%) | 162 (61.4) | 169 (64.0) | 163 (61.3)”

Table 1Find in source

The paper states that 'Institutional Review Boards/Independent Ethics Committees approved the protocol' and 'all participants provided written, informed consent before enrollment.' It also mentions compliance with the Declaration of Helsinki and ICH-GCP guidelines. This satisfies the requirements for human research.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial reports ethics approval by IRBs/Independent Ethics Committees and written informed consent, and states compliance with the Declaration of Helsinki and ICH-GCP.

Evidence

“Institutional Review Boards/Independent Ethics Committees approved the protocol (available at nejm.org (https://nejm.org/) ), and all participants provided written, informed consent before enrollment.”

MethodsFind in source

“the trial was conducted in accordance with the principles of the Declaration of Helsinki, the International Conference for Harmonization Good Clinical Practice guidelines, and applicable laws and regulations.”

MethodsFind in source

PASSReviewer 2· 95% conf

The trial reports ethics approval by IRBs/ethics committees, written informed consent, and compliance with the Declaration of Helsinki and ICH-GCP.

Evidence

MethodsFind in source

Baxdrostat is identified as the investigational drug with doses (1 mg and 2 mg) and regimen (once daily). The statistical software (SAS) is identified. No antibodies, cell lines, or other bench reagents are used, so those criteria are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (baxdrostat) is identified with dose and regimen, and the statistical software is named, which are the applicable resources for this drug trial.

Evidence

“Participants were randomly assigned 1:1:1 to receive baxdrostat 1 mg, baxdrostat 2 mg, or placebo once daily.”

MethodsFind in source

“All statistical analyses were performed using SAS software (SAS Institute Inc., Cary, NC, USA).”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational product (baxdrostat) is identified with dose and regimen, and the statistical software is named, but the manufacturer of baxdrostat is not explicitly stated in the text.

Evidence

“randomized (1:1:1) to baxdrostat 1mg, baxdrostat 2mg, or placebo once daily for 12 weeks.”

AbstractFind in source

“All statistical analyses were performed using SAS software (SAS Institute Inc., Cary, NC, USA).”

Statistical analysisFind in source

The primary analysis uses ANCOVA, which is named. Effect sizes are reported as LS mean differences with 95% CIs. P-values are reported as thresholds (e.g., P<0.0001) rather than exact values, which is common in large trials. Assumptions are handled by the pre-specified model. Data presentation includes forest plots and tables with per-group n. Mathematical plausibility is not applicable for large-N continuous outcomes.

Sub-criteria

tests namedADEQUATE

exact p valuesINADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The statistical analysis is well-described with named tests, effect sizes with confidence intervals, and software identification, though exact p-values are not always reported (only thresholds).

Evidence

“The primary analysis used analysis of covariance (ANCOVA) with treatment and hypertension status (uncontrolled, resistant) as factors and baseline seated-SBP as a covariate.”

Statistical analysisFind in source

“Estimated treatment differences of baxdrostat 1 mg and 2 mg relative to placebo were –8.7 mmHg (95% CI, –11.5 to –5.8; P<0.0001) and –9.8 mmHg (95% CI, –12.6 to –7.0; P<0.0001), respectively.”

ResultsFind in source

paraphrase[Results, Primary End Point]

“P<0.0001”

PASSReviewer 2· 90% conf

Statistical methods are well described with named tests, effect sizes with confidence intervals, and software identified, though exact p-values are not always reported (only thresholds).

Evidence

“The primary analysis used analysis of covariance (ANCOVA) with treatment and hypertension status (uncontrolled, resistant) as factors and baseline seated-SBP as a covariate.”

Statistical analysisFind in source

ResultsFind in source

There is no explicit data availability statement in the paper. The trial is registered on ClinicalTrials.gov, but that is not a data repository. No accession numbers or code sharing are mentioned. For a clinical trial, a data availability statement is required, and managed access is acceptable, but its absence is a reporting gap.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositNOT REPORTED

data availability statementNOT REPORTED

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

The paper does not include a data availability statement, and no data or code repositories are mentioned, which is a gap for a clinical trial.

Evidence

absence[Entire paper]

No data availability statement is present.

WARNReviewer 2· 80% conf

The paper does not include a data availability statement, and no data or code repositories are mentioned, which is a gap for a clinical trial.

Evidence

absence[Entire paper]

No data availability statement is present in the paper.

The trial is registered on ClinicalTrials.gov (NCT06034743). Methods are detailed enough for replication. Limitations are discussed (e.g., low number of ambulatory BP measurements, underrepresentation of women and Black participants). Conclusions are proportional to the results. Funding and COI are disclosed. No specific reporting guideline (e.g., CONSORT) is mentioned, but the paper follows standard clinical trial reporting.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper is transparent with trial registration, detailed methods, discussion of limitations, and proportional conclusions, though it does not reference a specific reporting guideline.

Evidence

“BaxHTN clinicaltrials.gov number, NCT06034743 (https://clinicaltrials.gov/ct2/show/NCT06034743)”

AbstractFind in source

“The present study has certain limitations. Ambulatory BP was measured in only a small number of participants.”

DiscussionFind in source

“The BaxHTN trial was funded by AstraZeneca.”

FundingFind in source

PASSReviewer 2· 90% conf

The paper is well-reported with trial registration, detailed methods, discussion of limitations, and proportional conclusions, though it does not explicitly reference a reporting guideline.

Evidence

“BaxHTN clinicaltrials.gov number, NCT06034743 (https://clinicaltrials.gov/ct2/show/NCT06034743)”

AbstractFind in source

“The present study has certain limitations. Ambulatory BP was measured in only a small number of participants.”

Discussion ¶5Find in source

Registered (2 IDs: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 25 references by DOI: 24 verified — 1 no DOI (shown, not verified).

2 data/code links checked; 2 live.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly consistency, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is methodologically robust and the conclusions are supported by the reported data. An informed reader should weigh the absence of a data availability statement and the minor discrepancy in the number randomized; these are reporting gaps that could warrant a correction or clarification, but they do not undermine the core findings.

1.
CRITICALstatistics
Correct or explain the statistically impossible value: PERCENT: 19.1% does not match the reported count 49/264
Demonstrable critical failure — blocks the verdict from passing.
2.
CRITICALstatistics
Correct or explain the statistically impossible value: PERCENT: 22.8% does not match the reported count 59/266
Demonstrable critical failure — blocks the verdict from passing.
3.
HIGHdata code
Add a data availability statement in the Methods or a dedicated section, specifying how de-identified participant data can be accessed (e.g., via a data-sharing platform or on reasonable request with a data access committee).
The absence of a data availability statement is a reporting gap for a clinical trial and is required by most journals.
4.
HIGHreporting
Reconcile the discrepancy in the number of participants randomized: the abstract states 794 were randomized and received treatment, while the results section says 796 were randomized and 794 received treatment.
An internal contradiction in the number randomized could confuse readers and may warrant a correction.
5.
MEDIUMcopyedit
Fix the typo 'Hyperkaemia' to 'Hyperkalemia' and add a closing parenthesis after '0.4' in the Results, Safety section.
Spelling inconsistency and missing parenthesis are minor but should be corrected for professionalism.
6.
MEDIUMcopyedit
Clarify the sentence in Results, Safety about percent change in eGFR to avoid repetition and ensure consistent use of '>' and '≥'.
The current phrasing is repetitive and confusing, which could obscure the safety data.
7.
MEDIUMcopyedit
Ensure consistent spacing of 'mg' (e.g., '1mg' should be '1 mg') in the Abstract and Results.
Inconsistent spacing is a minor formatting issue that should be standardized.
8.
MEDIUMreporting
Mention adherence to a reporting guideline such as CONSORT in the Methods or a footnote.
Explicitly referencing a reporting guideline enhances transparency and reproducibility.
9.
MEDIUMstatistics
Report exact p-values (e.g., P=0.00003) instead of thresholds like P<0.0001 where possible.
Exact p-values improve transparency and allow readers to assess the strength of evidence more precisely.
10.
MEDIUMrigor
Provide more detail on the randomization method (e.g., use of a central interactive response technology) in the Methods.
Specifying the randomization method strengthens the reproducibility of the trial design.
11.
MEDIUMdata code
Consider depositing the statistical analysis code (e.g., SAS programs) in a public repository to enhance reproducibility.
Sharing analysis code allows independent verification of the statistical results.
12.
LOWreporting
State the manufacturer of baxdrostat explicitly in the Methods or acknowledgments.
Identifying the manufacturer of the investigational product is standard practice for drug trials.
13.
LOWreporting
Clarify how limitations of prior research (e.g., HALO trial failure) were addressed in the study design, perhaps in the Discussion.
Explicitly addressing prior limitations strengthens the scientific premise.
14.
LOWreporting
Include a statement on whether the study protocol and statistical analysis plan are publicly available.
Public availability of the protocol and SAP enhances transparency and reproducibility.

Full text (34,763 chars)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.

Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, Olsson DS, Perl S, Shibata H, Wang JG, Wilderäng U, Wittes J, Williams B, BaxHTN Investigators

Read full text (PMC)

DOI

10.1056/NEJMoa2507109

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/3bf8085c-3ece-4c98-aae6-46fde7c90682" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/3bf8085c-3ece-4c98-aae6-46fde7c90682/badge" alt="Kaimen Rigor review — 1★ (Critical), 2 critical, 2 high issues for “Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

4993e021590f1746a22c242394ffd4b96bfaa11e616605fe65568374ffb595eb

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

1 / 5

Critical — a demonstrable failure

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

StatisticsImpossible or misreported statistic ×2−2★
IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
StatisticsPrinted percentage does not match its own count (capped) ×3−0.25★
ReportingData & code availability partially met−0.25★

A demonstrable critical failure caps the rating at the minimum, regardless of the deductions above.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 21 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Biggest issues2 demonstrable

01Printed percentage does not match its own countdemonstrable
criticalArithmeticrecomputedFull detail
19.1% does not match the reported count 49/264
“49 (19.1%)”
Safety
02Printed percentage does not match its own countdemonstrable
criticalArithmeticrecomputedFull detail
22.8% does not match the reported count 59/266
“59 (22.8%)”
Safety
03Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is change in seated systolic blood pressure (SBP), a surrogate for cardiovascular outcomes. The paper does not demonstrate target engagement at the tested doses (e.g., PK/PD or dose-exposure relationship) nor cite validated evidence linking SBP reduction to clinical outcomes in this context. Although SBP is a well-established surrogate for cardiovascular risk, the manuscript does not explicitly provide such validation or target engagement data.
“The primary efficacy end point was the change in seated-SBP, from baseline to week 12, assessed for each baxdrostat group versus placebo.”
Find in source
04Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
7% does not match the reported count 18/264
“18 (7.0%)”
Safety
05Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
12.6% does not match the reported count 33/264
“12.6%”
Safety
06Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
15.6% does not match the reported count 41/266
“15.6%”
Safety

Findings by category

301ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit6 minor suggestions

Numerical inconsistencies

3 findings · worst critical

Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions

2 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions only partially backed by the presented evidenceAssessed

5 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Evidence

Introduction ¶1Find in source

“An alternative therapeutic approach is direct inhibition of aldosterone synthase, which catalyzes the final three steps in aldosterone biosynthesis.”

Introduction ¶1Find in source

absence[Introduction]

The paper does not explicitly describe how limitations of prior research are addressed.

PASSReviewer 2· 90% conf

Evidence

Introduction ¶1Find in source

“Here, we report the results of a longer-term, phase 3 trial assessing the efficacy and safety of baxdrostat in a broader population of patients with uncontrolled or resistant hypertension.”

IntroductionFind in source

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodINADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Evidence

“Randomization was stratified by baseline hypertension status (uncontrolled hypertension, resistant hypertension) and baseline seated-SBP (<145, ≥145 mmHg).”

MethodsFind in source

“This multinational, randomized, double-blind, placebo-controlled phase 3 trial”

AbstractFind in source

Statistical analysisFind in source

PASSReviewer 2· 95% conf

Evidence

MethodsFind in source

Statistical analysisFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study reports key demographic and clinical characteristics including age, sex, race, and baseline blood pressure, which are adequate for a human trial.

Evidence

“Male sex – no. (%) | 162 (61.4) | 169 (64.0) | 163 (61.3)”

Table 1Find in source

paraphrase[Table 1]

“Race or ethnic group – no. (%) | White | 167 (63.3) | 165 (62.5) | 168 (63.2)”

“Diabetes – no. (%) | 110 (41.7) | 83 (31.4) | 110 (41.4)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, race, and baseline blood pressure, but some details on health status and comorbidities are limited.

Evidence

“Age – yrs | 61.9±11.6 | 59.8±11.8 | 61.8±11.7 | | Male sex – no. (%) | 162 (61.4) | 169 (64.0) | 163 (61.3)”

Table 1Find in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial reports ethics approval by IRBs/Independent Ethics Committees and written informed consent, and states compliance with the Declaration of Helsinki and ICH-GCP.

Evidence

MethodsFind in source

PASSReviewer 2· 95% conf

The trial reports ethics approval by IRBs/ethics committees, written informed consent, and compliance with the Declaration of Helsinki and ICH-GCP.

Evidence

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (baxdrostat) is identified with dose and regimen, and the statistical software is named, which are the applicable resources for this drug trial.

Evidence

“Participants were randomly assigned 1:1:1 to receive baxdrostat 1 mg, baxdrostat 2 mg, or placebo once daily.”

MethodsFind in source

“All statistical analyses were performed using SAS software (SAS Institute Inc., Cary, NC, USA).”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational product (baxdrostat) is identified with dose and regimen, and the statistical software is named, but the manufacturer of baxdrostat is not explicitly stated in the text.

Evidence

“randomized (1:1:1) to baxdrostat 1mg, baxdrostat 2mg, or placebo once daily for 12 weeks.”

AbstractFind in source

“All statistical analyses were performed using SAS software (SAS Institute Inc., Cary, NC, USA).”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesINADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The statistical analysis is well-described with named tests, effect sizes with confidence intervals, and software identification, though exact p-values are not always reported (only thresholds).

Evidence

“The primary analysis used analysis of covariance (ANCOVA) with treatment and hypertension status (uncontrolled, resistant) as factors and baseline seated-SBP as a covariate.”

Statistical analysisFind in source

ResultsFind in source

paraphrase[Results, Primary End Point]

“P<0.0001”

PASSReviewer 2· 90% conf

Statistical methods are well described with named tests, effect sizes with confidence intervals, and software identified, though exact p-values are not always reported (only thresholds).

Evidence

“The primary analysis used analysis of covariance (ANCOVA) with treatment and hypertension status (uncontrolled, resistant) as factors and baseline seated-SBP as a covariate.”

Statistical analysisFind in source

ResultsFind in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositNOT REPORTED

data availability statementNOT REPORTED

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

The paper does not include a data availability statement, and no data or code repositories are mentioned, which is a gap for a clinical trial.

Evidence

absence[Entire paper]

No data availability statement is present.

WARNReviewer 2· 80% conf

The paper does not include a data availability statement, and no data or code repositories are mentioned, which is a gap for a clinical trial.

Evidence

absence[Entire paper]

No data availability statement is present in the paper.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper is transparent with trial registration, detailed methods, discussion of limitations, and proportional conclusions, though it does not reference a specific reporting guideline.

Evidence

“BaxHTN clinicaltrials.gov number, NCT06034743 (https://clinicaltrials.gov/ct2/show/NCT06034743)”

AbstractFind in source

“The present study has certain limitations. Ambulatory BP was measured in only a small number of participants.”

DiscussionFind in source

“The BaxHTN trial was funded by AstraZeneca.”

FundingFind in source

PASSReviewer 2· 90% conf

The paper is well-reported with trial registration, detailed methods, discussion of limitations, and proportional conclusions, though it does not explicitly reference a reporting guideline.

Evidence

“BaxHTN clinicaltrials.gov number, NCT06034743 (https://clinicaltrials.gov/ct2/show/NCT06034743)”

AbstractFind in source

“The present study has certain limitations. Ambulatory BP was measured in only a small number of participants.”

Discussion ¶5Find in source

Registered (2 IDs: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 25 references by DOI: 24 verified — 1 no DOI (shown, not verified).

2 data/code links checked; 2 live.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly consistency, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
CRITICALstatistics
Correct or explain the statistically impossible value: PERCENT: 19.1% does not match the reported count 49/264
Demonstrable critical failure — blocks the verdict from passing.
2.
CRITICALstatistics
Correct or explain the statistically impossible value: PERCENT: 22.8% does not match the reported count 59/266
Demonstrable critical failure — blocks the verdict from passing.
3.
HIGHdata code
Add a data availability statement in the Methods or a dedicated section, specifying how de-identified participant data can be accessed (e.g., via a data-sharing platform or on reasonable request with a data access committee).
The absence of a data availability statement is a reporting gap for a clinical trial and is required by most journals.
4.
HIGHreporting
Reconcile the discrepancy in the number of participants randomized: the abstract states 794 were randomized and received treatment, while the results section says 796 were randomized and 794 received treatment.
An internal contradiction in the number randomized could confuse readers and may warrant a correction.
5.
MEDIUMcopyedit
Fix the typo 'Hyperkaemia' to 'Hyperkalemia' and add a closing parenthesis after '0.4' in the Results, Safety section.
Spelling inconsistency and missing parenthesis are minor but should be corrected for professionalism.
6.
MEDIUMcopyedit
Clarify the sentence in Results, Safety about percent change in eGFR to avoid repetition and ensure consistent use of '>' and '≥'.
The current phrasing is repetitive and confusing, which could obscure the safety data.
7.
MEDIUMcopyedit
Ensure consistent spacing of 'mg' (e.g., '1mg' should be '1 mg') in the Abstract and Results.
Inconsistent spacing is a minor formatting issue that should be standardized.
8.
MEDIUMreporting
Mention adherence to a reporting guideline such as CONSORT in the Methods or a footnote.
Explicitly referencing a reporting guideline enhances transparency and reproducibility.
9.
MEDIUMstatistics
Report exact p-values (e.g., P=0.00003) instead of thresholds like P<0.0001 where possible.
Exact p-values improve transparency and allow readers to assess the strength of evidence more precisely.
10.
MEDIUMrigor
Provide more detail on the randomization method (e.g., use of a central interactive response technology) in the Methods.
Specifying the randomization method strengthens the reproducibility of the trial design.
11.
MEDIUMdata code
Consider depositing the statistical analysis code (e.g., SAS programs) in a public repository to enhance reproducibility.
Sharing analysis code allows independent verification of the statistical results.
12.
LOWreporting
State the manufacturer of baxdrostat explicitly in the Methods or acknowledgments.
Identifying the manufacturer of the investigational product is standard practice for drug trials.
13.
LOWreporting
Clarify how limitations of prior research (e.g., HALO trial failure) were addressed in the study design, perhaps in the Discussion.
Explicitly addressing prior limitations strengthens the scientific premise.
14.
LOWreporting
Include a statement on whether the study protocol and statistical analysis plan are publicly available.
Public availability of the protocol and SAP enhances transparency and reproducibility.

Full text (34,763 chars)Analyzed: Aug 15, 2026